Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. - Wikidata - awgldk - TriplyDB

Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions.

Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions.

http://www.wikidata.org/entity/Q54316297

about

Cutaneous manifestations of hepatitis C in the era of new antiviral agents Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective Pruritus in Systemic Diseases: A Review of Etiological Factors and New Treatment Modalities Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis Jaundice associated pruritis: a review of pathophysiology and treatment Bile acid signaling in metabolic disease and drug therapy Neural processing of itch.Clinical application of transcriptional activators of bile salt transporters.Recent advances in the management of pruritus in chronic liver diseases Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.Not all (bile acids) who wander are lost: the first report of a patient with an isolated NTCP defect Management of pruritus in chronic liver disease.Chlorpromazine-induced perturbations of bile acids and free fatty acids in cholestatic liver injury prevented by the Chinese herbal compound Yin-Chen-Hao-Tang.Potentiation of the transient receptor potential vanilloid 1 channel contributes to pruritogenesis in a rat model of liver disease.Nuclear receptors as drug targets in cholestatic liver diseases.Proposed therapies in primary biliary cholangitis.Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases.Pruritus: an overview. What drives people to scratch an itch?Refractory pruritus in primary biliary cirrhosis Natural history and management of primary biliary cirrhosis.Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.Diagnosis and Management of Chronic Pruritus: An Expert Consensus Review.Bile acids reach out to the spinal cord: new insights to the pathogenesis of itch and analgesia in cholestatic liver disease Bile acid transporters and regulatory nuclear receptors in the liver and beyond Bile acid receptors as targets for drug development.Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.Primary biliary cirrhosis in adults.Pruritus in cholestasis: facts and fiction.Novel therapeutic targets in primary biliary cirrhosis.Chronic pruritus in the elderly: pathophysiology, diagnosis and management.Primary sclerosing cholangitis: a clinical update.A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis.Advances in therapeutic strategies for the treatment of pruritus.Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease.The impact of intensified hemodialysis on pruritus in an end stage renal disease patient with biliary ductopenia.Treatment of pruritus with Prometheus dialysis and absorption system in a patient with benign recurrent intrahepatic cholestasis.Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study.Prevalence and Relevance of Pruritus in Pregnancy.Complications, symptoms, quality of life and pregnancy in cholestatic liver disease.[Intrahepatic cholestasis of pregnancy : Rare but important].

P2860

Q26773669-FB063AB7-D91D-4092-9C60-879EE1F68520 Q26781780-4FACF164-553F-4DBE-8651-2891A843943D Q26799175-97076D9F-BBB0-4472-B0AA-999490ACCFB4 Q26992087-49A92AF5-3E32-4C81-9565-E39953F25FAA Q28084371-1146D3AC-2E13-48F1-B554-9CDE2E6AB46F Q28244875-849C891C-B98A-4736-9127-5F1474A1F6F5 Q30428749-A5ADC8F9-7A86-4825-AB32-C62CE42F7931 Q33709930-82BB1FFF-FFFF-4751-811B-7D171DFFDF0C Q33719935-FBA9776B-1104-47E1-B68E-AA6DAB7FF2DE Q33721771-540CD888-A527-40E1-B0C8-F637FFDA2C8C Q34791055-F077CE81-E2C8-4757-B089-A2DCEB449706 Q35226847-8CE1E96B-7AEB-4B73-AA16-8E9A276088C1 Q35607454-02179E3E-D5EC-4A2A-B4A5-13A47AED3B23 Q36742184-959F5F99-CFBD-4B5E-ACA1-BB601F6061D3 Q36786270-A9AFC03D-9014-4082-8411-0C0EEB3193C9 Q37072380-7895C853-2EB6-4DD7-B811-75491596D816 Q37163154-E767AEC5-F57E-4452-996A-EB24CD029ED2 Q37272308-61985609-50C8-4457-BBB6-EC4AE9C45EBD Q37314381-52C6245D-E897-4F66-A6D7-D5B494ABDFEC Q37355843-E40D1CE9-3A84-4155-8064-0E16A3FDBC8E Q37422766-D22E8696-9177-41A8-A439-35FFCD33993A Q37618589-A016A9C5-CB67-49DA-88B8-74D36D8BD7A0 Q37666088-0533993C-62E0-4326-BD8D-486B51FBF028 Q38033967-81F0CE3D-0EAC-481F-B95C-8AD599D9F821 Q38132058-385E086D-CB02-4510-A9CF-8C695686D045 Q38175055-487D69D2-C034-4B58-AED6-25BB1FFC7839 Q38192045-B918DE91-EEEE-40D3-8CF7-093EB2438D0C Q38210112-CF1F1D3D-9D7D-4DF2-B870-75D272E44FD5 Q38342107-CE87702E-791C-479F-9922-14E6B518D5CD Q38360710-7796AEC6-209A-4C14-9085-E46AA01CCECC Q38485235-F755DB49-BF7F-4823-9DEA-2E05FB76C6E4 Q38637490-C41CC0AA-C3C2-4F31-9374-E1784498479C Q38656850-311D5E45-4E16-4FD9-9BAD-27255469A307 Q39116967-85306126-56C8-40AF-98E7-8ACA1F1BEF02 Q41908724-C3B2DA1E-E1C8-414B-BC7A-65918C4D4E3F Q44832218-8E76FAE7-88ED-4BDE-8177-4AD12849611E Q46111528-A3ABFC5B-F8BB-49EB-A48E-9F0E2EFF4174 Q47154799-5CEF63F6-E487-4F17-8F87-2108E45DBA30 Q48331749-5198C801-4093-44A6-8C4D-CE35CE19A04C Q51273998-501ED850-C917-4B4C-AFA2-C24C150C43F8

P2860

Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions.

http://www.wikidata.org/entity/Q54316297

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Serum autotaxin is increased i ...... to therapeutic interventions.

@en

Serum autotaxin is increased i ...... to therapeutic interventions.

@nl

type

label

Serum autotaxin is increased i ...... to therapeutic interventions.

@en

Serum autotaxin is increased i ...... to therapeutic interventions.

@nl

prefLabel

Serum autotaxin is increased i ...... to therapeutic interventions.

@en

Serum autotaxin is increased i ...... to therapeutic interventions.

@nl

P1433

Q54316297-A5A2ABF9-7103-4F1C-886C-1D730E657077

P1476

Q54316297-55C25947-4D9B-4D0F-967E-A4F87737D0D4

P2093

Q54316297-0B9A0DC4-7E49-4B0D-BEB5-61B8CB52BCBE

Q54316297-1929F12D-F95A-497F-BAD0-464D05F5DCBA

Q54316297-1EE3C3A5-C485-49A1-9FDC-212B711027F6

Q54316297-1FA5F1AD-C7E3-4119-8B3B-80807EB0601F

Q54316297-3358B442-3996-4415-8376-1B6EA552C353

Q54316297-3691BFC9-D7E4-4E9F-8D4A-BA1898341780

Q54316297-3A8F33FA-4055-4A0B-8ABF-E1D5CED19956

Q54316297-4C680C6D-A011-4434-899B-7B4B9E5D5370

Q54316297-8637C96F-F005-498E-B906-5C231AE494D0

Q54316297-9A0EAF4F-B395-4B22-88A9-24799AAC3C55

P2860

Q54316297-04289BA2-83F4-4C2B-B467-C3466AB170ED

Q54316297-0ABFA473-756B-48C7-8D4D-1EC1F1B497A4

Q54316297-1D98C9E3-4B33-4556-964F-7F0C83433F76

Q54316297-1DD90382-2A29-43B1-A5D8-37070F59EA33

Q54316297-25BC608B-AC60-469C-A590-CA6EF5639F9F

Q54316297-2935AE12-F50D-4C70-9F1D-372FEC82B181

Q54316297-2A08E09A-FBDC-4041-8D8A-D464233C1891

Q54316297-2E83DB8A-21A8-495A-B9CF-E668D92C0F60

Q54316297-2EA9B7B1-AFBA-4FE4-BF05-F10A9C6432ED

Q54316297-305D5A36-3A82-4771-A97C-F8B965375D80

P304

Q54316297-13DE0C10-D367-4033-898E-D6BD21615AD8

P31

Q54316297-59D1282D-CF67-4CDD-BEBD-B9B7BFE89287

P356

Q54316297-F3F52046-6102-4991-9347-D11B6900B611

P407

Q54316297-8D6EBD4C-A59D-4FC7-B17A-D04C8AA55F4C

P433

Q54316297-73069386-989F-4ED4-9331-D471F5A12F00

P478

Q54316297-9571E1EE-420A-4888-8CE5-19A43D0B29DE

P50

Q54316297-3B8845E8-E7E4-4486-A391-E9CE8B219DAB

Q54316297-7671C2A4-D977-4F83-A4B1-8EDA3947CBB9

P577

Q54316297-C4958CF1-C49B-4B10-AD0C-066A193FB152

P5875

Q54316297-24899B00-57F3-488B-A258-AB072F7BE14E

P698

Q54316297-1F67145F-E79F-4872-93C9-8A0D09CA49D4

P356

P1433

P1476

Serum autotaxin is increased i ...... to therapeutic interventions.

@en

P2093

Andreas Engert

http://www.w3.org/2001/XMLSchema#string

Christian Rust

http://www.w3.org/2001/XMLSchema#string

Edith M M Kuiper

http://www.w3.org/2001/XMLSchema#string

Henk R van Buuren

http://www.w3.org/2001/XMLSchema#string

Karel J van Erpecum

http://www.w3.org/2001/XMLSchema#string

Katrin S Reiners

http://www.w3.org/2001/XMLSchema#string

Nathan A Davies

http://www.w3.org/2001/XMLSchema#string

Pamela Leckie

http://www.w3.org/2001/XMLSchema#string

Rajiv Jalan

http://www.w3.org/2001/XMLSchema#string

Remco van Dijk

http://www.w3.org/2001/XMLSchema#string

P2860

The emerging role of lysophosphatidic acid in cancer

The neurobiology of itch

Lysophosphatidic acid is a potential mediator of cholestatic pruritus

High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis

Autotaxin--an LPA producing enzyme with diverse functions.

Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis.

Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.

Pathogenesis and treatment of pruritus in cholestasis.

Epidemiology of itch: adding to the burden of skin morbidity.

Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers.

P304

1391-1400

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.25748

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Frank G. Schaap

Andreas E Kremer

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223986309

http://www.w3.org/2001/XMLSchema#string

P698

22473838

http://www.w3.org/2001/XMLSchema#string